Sweden · Delayed Price · Currency is SEK Devyser Diagnostics AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 24% revenue growth in fixed currencies, positive EBIT for the fourth straight quarter, and strong gross margins. The Cybergene acquisition and new Illumina agreement are set to boost future growth, with continued focus on profitable expansion and cash flow.
Fiscal Year 2025
-
Record Q4 sales and profitability were achieved, with EBIT margin over 20% and strong cash flow. Growth was driven by new product launches, strategic acquisitions, and major partnerships, while cost discipline and regulatory progress support a positive outlook.
-
Q3 saw record revenue and improved profitability, with positive EBIT and strong growth in the Americas and Italy. New product launches and efficiency measures support a positive outlook, while reimbursement delays and gradual tender ramp-ups remain key watchpoints.
-
Record Q2 revenue and EBIT were driven by strong U.S. and distributor sales, new product launches, and operational efficiencies. The company is on track to meet its 2026 financial targets, with a robust cash position and continued investment in innovation.
-
Q1 2025 revenue grew 8% year-over-year to SEK 54.8 million, with gross margin rebounding to 83.4%. Strategic focus on clinical genetics and transplantation, new product launches, and regulatory milestones support confidence in meeting 2025 growth and profitability targets.
Fiscal Year 2024
-
Q4 2024 marked the first profitable quarter, with revenue up 41.5% year-over-year and strong growth in EMEA and the Americas. Strategic partnerships, regulatory milestones, and a robust cash position support continued expansion and profitability focus in 2025.
-
Strong growth continues across hereditary, oncology, and transplantation, with a strategic shift toward NGS and software. U.S. expansion is prioritized via a dual lab/kit model, aiming for rapid Medicare coverage and FDA approvals. Financial targets for growth, margin, and profitability remain on track.
-
Q3 saw modest revenue growth and a temporary drop in gross margin due to facility move costs, but strong performance in Europe and Asia and a major order from Thermo Fisher set up a robust Q4. Strategic FDA partnership and new product launches are expected to drive future growth.
-
Record Q2 sales and strong organic growth were driven by major tender wins, expanded global partnerships, and high-margin consumables. One-off costs from facility moves and U.S. expansion impacted EBIT, but guidance remains for continued high growth and margin improvement.